Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is limited, poorly characterized information about adverse events occurring during maintenance treatment of bipolar disorder. We aimed to determine adverse event rates during treatment with lithium, valproate, olanzapine, and quetiapine. METHODS AND FINDINGS: We conducted a propensity score adjusted cohort study using nationally representative United Kingdom electronic health records from January 1, 1995, until December 31, 2013. We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment. Adverse outcomes were chronic kidney disease, thyroid disease, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, cardiovascular disease, and hepatotoxicity. The propensity score included important demographic, physical health, and mental health predictors of drug treatment allocation. The median duration of drug treatment was 1.48 y (interquartile range 0.64-3.43). Compared to patients prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic kidney disease stage 3 or more severe, following adjustment for propensity score, age, and calendar year, and accounting for clustering by primary care practice (valproate hazard ratio [HR] 0.56; 95% confidence interval [CI] 0.45-0.69; p < 0.001, olanzapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47-0.80; p < 0.001). Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and olanzapine (HR 0.48; 95% CI 0.29-0.77; p = 0.003), compared to those taking lithium. Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapine HR 0.31; 95% CI 0.13-0.73; p = 0.007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiapine HR 0.23; 95% CI 0.07-0.73; p = 0.013) were also reduced relative to lithium. However, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24-2.20; p < 0.001) than in individuals prescribed lithium, as were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p = 0.017). We found no significant difference in rates of chronic kidney disease stage 4 or more severe, type 2 diabetes mellitus, cardiovascular disease, or hepatotoxicity. Despite estimates being robust following sensitivity analyses, limitations include the potential for residual confounding and ascertainment bias and an inability to examine dosage effects. CONCLUSIONS: Lithium use is associated with more renal and endocrine adverse events but less weight gain than commonly used alternative mood stabilizers. Risks need to be offset with the effectiveness and anti-suicidal benefits of lithium and the potential metabolic side effects of alternative treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Matching Methods for Causal Inference: A Review and a Look Forward
Stuart, E. A. (2010) · Statistical Science · doi:10.1214/09-sts313 · Cited by 5,478 · cited 1×
“In this way, use of a PS aims to replicate a randomized experiment as closely as possible by obtaining treatment groups with similar covariate distributions [48].”
MethodPartial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 1×
“These risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options [5,68].”
BackgroundSelf-citationThe Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Miura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., Salanti, G., Motomura, K., Shimano-Katsuki, S., Leucht, S., et al. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70314-1 · Cited by 364 · cited 2×
“Kingdom National Institute for Health and Care Excellence (NICE) guidelines [3], a metaanalysis [4], and a network meta-analysis [5] all suggested that lithium should be seen as firstline monotherapy, whereas previous guidelines from around the world also recommended valproate, lamotrigine, carbamazepine, olanzapine,…”
BackgroundSelf-citationTesting for chronic kidney disease: a position statement from the National Kidney Foundation
Vassalotti, J. A., Stevens, L. A., & Levey, A. S. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.06.013 · Cited by 331 · cited 1×
“73 m(2)) [34,35] (if eGFR was unavailable we calculated it from available creatinine blood tests using the CKD-EPI equation [36]), hypothyroidism (or a TSH of>10 mU/L), hyperthyroidism (or a TSH<0.”
Method
Cited by
Lithium side effects and toxicity: prevalence and management strategies
Gitlin, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0068-y · Cited by 531
Lithium and suicide in mood disorders: Updated meta‐review of the scientific literature
Smith, K. A., & Cipriani, A. (2017) · Bipolar Disorders · doi:10.1111/bdi.12543 · Cited by 247
Tondo, L., Abramowicz, M., Alda, M., Bauer, M., Bocchetta, A., Bolzani, L., Calkin, C. V., Chillotti, C., Hidalgo-Mazzei, D., Manchia, M., et al. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0096-2 · Cited by 125
Fusar-Poli, L., Amerio, A., Cimpoesu, P., Natale, A., Salvi, V., Zappa, G., Serafini, G., Amore, M., Aguglia, E., & Aguglia, A. (2020) · Medicina · doi:10.3390/medicina57010028 · Cited by 28
Lithium Treatment in Children and Adolescents
Duffy, A., & Grof, P. (2018) · Pharmacopsychiatry · doi:10.1055/a-0575-4179 · Cited by 22
“There is also certain disenchantment with neuroleptics as long-term mood stabilizers as the expectation of effectiveness translating from acute to prophylaxis, initially hyped by the industry, has not been achieved, while side effects, including metabolic syndrome, have been more extensively documented [22].”
Background
Metadata
- Authors
- Hayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-08-02
- Volume
- 13
- Issue
- 8
- Pages
- e1002058
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2481798045
- Cited by
- 115
- References
- 18
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. https://app.cochat.ai/papers/10.1371/journal.pmed.1002058
- The paper
- Hayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. J. (2016). Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.